Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
TLPPF Stock Chart & Stats
$10.38
$0.06(0.36%)
At close: 4:00 PM EST
$10.38
$0.06(0.36%)
Day’s Range― - ―
52-Week Range$5.91 - $19.99
Previous CloseN/A
Volume500.00
Average Volume (3M)956.00
Market Cap
$3.51B
Enterprise Value$5.83B
Total Cash (Recent Filing)$212.74M
Total Debt (Recent Filing)$785.24M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 20, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding339,113,900
10 Day Avg. Volume507
30 Day Avg. Volume956
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue4.77
Enterprise Value/Gross Profit9.39
Enterprise Value/Ebitda157.29
Forecast
1Y Price Target
$17.36Price Target Upside67.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.03
Revenue Forecast (FY)$680.04M
Bulls Say, Bears Say
Bulls Say
Diagnostic Market StrategyTwo-product PSMA PET approach targets different payor reimbursement preferences and helps stabilize diagnostic sales amid pricing pressure, supporting broader market access.
Regulatory And Clinical Trial MomentumPlanned resubmission of the brain imaging agent Pixclara combined with BiPASS dosing in U.S. patients and strong recruitment abroad could advance regulatory review and support label expansion that increases scan volumes.
Therapeutics Pipeline InvestmentReinvestment of diagnostic revenue into pivotal therapeutic programs TLX591, TLX250 and TLX101 creates potential for future oncology launches beyond products currently included in guidance.
Bears Say
Legacy Product PerformanceSoftness in legacy RLS products presents a headwind to overall revenue growth and may weigh on near-term sales metrics.
Regulatory, Safety And Legal RiskFuture upside depends on regulatory approvals, guideline placement and resolution of safety data and an SEC probe, any of which could delay launches or create pricing pressure.
Valuation And Analyst SentimentA reduced price target and classification of the investment as high risk reflect tempered expectations and elevated uncertainty about the stock's valuation trajectory.
Telix Pharmaceuticals News
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $5.91 and its highest was $19.99 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $3.51B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 127 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -$0.012 earnings per share for the quarter, missing the consensus estimate of $0.04 by -$0.052.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.02.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,113,900 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -$0.012 in its last earnings report, missing expectations of $0.04. Following the earnings report the stock price went up 15.327%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.36 (67.24% Upside)
$17.36 (67.24% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 94%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.53%
12-Months-Change
Fundamentals
Return on Equity
-2.08%
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLPPF Company Deck
TLPPF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and strategic picture: very strong top-line growth (56% FY2025), a high-margin, cash-generative Precision Medicine engine, successful recent FDA approval and launches, a deep late-stage pipeline with three pivotal therapeutic programs, and upgraded R&D investment to accelerate therapeutics. Offsetting these strengths are regulatory setbacks that require resubmissions (Pixclara and Zircaix), modest consolidated profitability due to aggressive reinvestment (adjusted EBITDA $39.5M), a lean year-end cash balance after major investments, and near-term concentration in the U.S. reimbursement environment. Management has outlined a clear plan to self-fund pipeline advancement and scale manufacturing, but execution and timing of regulatory approvals and the ramp of international reimbursement remain key risks.View all TLPPF earnings summariesTLPPF Stock 12 Month Forecast
Average Price Target
$17.36
▲(67.24% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Ownership Overview
6.29% Insiders
1.37% Mutual Funds
― Other Institutional Investors
88.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---